Proceedings of Thirty Third Annual General Meeting.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Titan Biotech Limited held its 33rd Annual General Meeting on September 26, 2025, via Video Conferencing, from 3:00 PM to 3:58 PM IST. A total of 236 members attended (9 promoter group and 227 public shareholders). The meeting was chaired by Managing Director Mr. Naresh Kumar Singla. Members transacted 15 resolutions including adoption of audited financial statements (standalone and consolidated) for FY ended March 31, 2025, declaration of dividend on equity shares, re-appointment of three directors liable to retire by rotation, and re-appointment of both Managing Directors (Mr. Naresh Kumar Singla and Mr. Suresh Chand Singla). Special business included appointment of a new Secretarial Auditor, increase in remuneration of two Whole-Time Directors, regularization of a new Independent Director, approval of material related party transactions, and authorization for loans and mortgage of company property for borrowing.
For retail shareholders, the key takeaways are the proposed dividend on equity shares, higher remuneration for two Whole-Time Directors (which may impact future expenses), and approval of material related party transactions that warrant attention. The re-appointment of both Managing Directors signals continuity in leadership. Voting results are awaited and will be disclosed separately.